Analysis of the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR, and CBR

TL;DR

This study compares the effectiveness of a chemotherapy regimen with and without albumin-bound paclitaxel in treating breast cancer, finding improved outcomes with the combined treatment.

Contribution

The study demonstrates that adding albumin-bound paclitaxel to pirarubicin and cyclophosphamide improves chemotherapy outcomes in breast cancer patients.

Findings

The observation group had higher PCR, ORR, and CBR compared to the control group.

The observation group showed significantly lower levels of CA152, CA125, TPS, HER-2, Ki-67, and EGFR.

Adverse reactions were slightly higher in the observation group but not statistically significant.

Abstract

To explore the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR and CBR.

This was a retrospective study. During the period from January 2022 to December 2023, ninety patients with breast cancer who were treated in The First People’s Hospital of Changde City were included as the research objects. Based on the principle of randomized control, the above patients were divided into the control group (45 cases, treated with pirarubicin and cyclophosphamide) and the observation group (45 cases, treated with albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide) by the random number table. Compared the chemotherapy effect and safety of the two groups.

After treatment, the PCR, ORR and CBR of the observation group were higher than those of the control group, while the levels of CA152, CA125, TPS, HER-2, Ki-67 and EGFR were lower than those of the control group, and the differences were statistically significant (P<0.05). The incidence of adverse reactions was 33.33% (15/45), which was slightly higher than that of 28.89% (13/45) in the control group, the difference was not statistically significant (P>0.05).

Albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide is a safe regimen that can further enhance the effect of neoadjuvant chemotherapy in the treatment of breast cancer, and it has a certain value for dissemination in the treatment of breast cancer can further enhance the effect of neoadjuvant chemotherapy in patients, which is of certain value for clinical promotion.